Stock Events

Stock Events

Q/C Technologies 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DQS.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences is a biopharmaceutical company that competes with MyMD in the development of treatments for viral diseases, inflammatory and fibrotic diseases, which overlaps with MyMD's focus on immune-mediated diseases.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie competes in the immunology and oncology sectors, directly challenging MyMD's efforts in developing therapies for immune system diseases and cancer.
AMGEN
AMGN
Mkt Cap187.56B
Amgen is a biotech firm focusing on novel therapies in areas like inflammation, which competes with MyMD's research into immune system modulation.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb operates in the biopharmaceutical field, focusing on cancer and immune system disorders, directly competing with MyMD's therapeutic areas.
Merck
MRK
Mkt Cap298.84B
Merck is known for its work in pharmaceuticals and vaccines, including treatments for immune system disorders, making it a competitor to MyMD.
Pfizer
PFE
Mkt Cap161.09B
Pfizer develops and manufactures drugs and vaccines, including for autoimmune diseases, competing with MyMD's focus on immune system modulation.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals specializes in medicines for serious conditions, including immune-mediated diseases, directly competing with MyMD's focus areas.
Novartis
NVS
Mkt Cap297.32B
Novartis focuses on a broad range of healthcare areas, including advanced therapies in immunology and oncology, competing with MyMD.
Biogen
BIIB
Mkt Cap26.03B
Biogen focuses on neurology and rare diseases but also competes in the broader biopharmaceutical market against companies like MyMD.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals concentrates on treating the underlying causes of diseases in areas like cystic fibrosis, which involves modulation of the immune system, indirectly competing with MyMD.

About

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Show more...
CEO
Dr. Christopher C. Chapman Jr., M.D.
Employees
10
Country
Germany
ISIN
US62856X3008

Listings

F
DE
DQS.F
XNAS
US
QCLS
MU
DE
DQS.MU
BOATS
BOATS
QCLS.BOATS

0 Comments

Share your thoughts

FAQ

What is Q/C Technologies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Q/C Technologies stocks are traded under the ticker DQS.MU.
How many employees does Q/C Technologies have?▼
As of April 12, 2026, the company has 10 employees.
In which sector is Q/C Technologies located?▼
Q/C Technologies operates in the Health & Wellness sector.
When did Q/C Technologies complete a stock split?▼
Q/C Technologies has not had any recent stock splits.
Where is Q/C Technologies headquartered?▼
Q/C Technologies is headquartered in Baltimore, Germany.